Related Experiment Videos
Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line
Yuki Nabeta1, Satoshi Kawaguchi, Hiroeki Sahara
1Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, S. 1, W. 16, Chuo-ku, 060-8543, Sapporo, Japan.
Abstract:
Because of the difficulty of developing pairs of osteosarcoma cell lines and cytotoxic T lymphocytes (CTLs), no osteosarcoma tumor antigens that are useful for antiosteosarcoma immunotherapy have yet been identified. In parallel with continuous attempts to develop such pairs from osteosarcoma, we employed serological identification using a recombinant expression cloning (SEREX) method to identify B cell-defined antigens. Consequently, a human osteosarcoma cell line, OS2000, was established from a primary osteosarcoma of a patient cured of hereditary retinoblastoma. Repetitious in vitro stimulations by OS2000 cells to the autologous peripheral T cells induced cytotoxic activity in the autologous osteosarcoma cells but not in the nontumor cells. The cytotoxicity was inhibited by anti-HLA class I monoclonal antibody. SEREX analysis revealed that autologous humoral immunity reacted to two proteins expressed in OS2000. One was the self HLA-Cw*0102 molecule, and the other was wild-type smooth muscle myosin light chain (SMMLC). However, no antigenicity of these proteins was seen versus the sera of the other patients. In conclusion, our results demonstrated the presence of host cellular and humoral immune responses to autologous osteosarcoma cells. This offered the opportunity to identify osteosarcoma antigens recognized by autologous immunity.
Insights
Researchers identified host immune responses against osteosarcoma cells, paving the way for new immunotherapies. Autologous cellular and humoral immunity targets were found, offering potential for osteosarcoma antigen discovery.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Developing osteosarcoma cell lines and cytotoxic T lymphocytes (CTLs) for immunotherapy research is challenging.
- No osteosarcoma tumor antigens have been identified for effective anti-osteosarcoma immunotherapy.
- Identifying tumor antigens is crucial for advancing osteosarcoma treatment.
Purpose of the Study:
- To identify osteosarcoma tumor antigens recognized by autologous immune responses.
- To investigate cellular and humoral immunity against osteosarcoma.
- To establish a foundation for developing novel osteosarcoma immunotherapies.
Main Methods:
- Established a human osteosarcoma cell line (OS2000) from a patient with hereditary retinoblastoma.
- Used serological identification with a recombinant expression cloning (SEREX) method to identify B cell-defined antigens.
- Induced and analyzed cytotoxic T lymphocyte (CTL) activity against autologous tumor cells.
Main Results:
- Autologous T cells stimulated by OS2000 cells exhibited cytotoxicity against osteosarcoma cells, inhibited by anti-HLA class I antibody.
- SEREX analysis identified two proteins eliciting autologous humoral immunity: HLA-Cw*0102 and wild-type smooth muscle myosin light chain (SMMLC).
- These identified proteins showed no antigenicity in sera from other osteosarcoma patients, suggesting autologous specificity.
Conclusions:
- Demonstrated the presence of host cellular and humoral immune responses specifically targeting autologous osteosarcoma cells.
- Highlighted the potential of identified antigens for developing personalized anti-osteosarcoma immunotherapies.
- The study provides a critical step towards identifying actionable osteosarcoma antigens for clinical application.